吉西他滨在宫颈癌化疗中的应用  

Clinical application of gemcitabine in chemotherapy of cervical cancer

作　　者：裴红[1] 魏敏[1] 周宝琴[1] 

机构地区：[1]江苏省肿瘤医院妇瘤科,江苏南京210009

出　　处：《医学研究生学报》2004年第11期991-992,995,共3页Journal of Medical Postgraduates

摘　　要：目的 :探讨吉西他滨 (Gemcitabine)在宫颈癌化疗中的作用。　方法 :选择初治的巨块型宫颈癌 10例 ,分为放、化疗组和单纯放疗组 ,每组各 5例 ,分别在进行放、化疗和单纯放疗后进行手术治疗 ,对照两组患者情况和肿瘤病理变化。另有复发宫颈癌 3例 ,应用以吉西他滨为主的联合化疗并观察治疗效果。　结果 :初治患者中放、化疗组完全缓解 3例 ,单纯放疗组仅 1例。 3例复发患者中有 1例症状暂时缓解。　结论 :吉西他滨用于巨块型宫颈癌初治患者的新辅助化疗有较好的疗效 。Objective: To investigate the efficacy of gemcitabine in chemotherapy of cervical carcinoma. Methods:10 untreated cervical carcinoma patients had been divided into two groups,5 cases were treated with neoadjuvant chemotherapy and radiotherapy,others were treated only with radiotherapy. All patients were operated and compared the pathologic changes of cancers. Moreover 3 cases with recurrent tumors had been treated with gemcitabine and other agents . Results: The rate of complete response(CR) was 60% in group of neoadjuvant chemotherapy and 20% in patients with only radiotherapy. Only one case achieved partial response (PR) in patients with recurrence. Conclusion: The neoadjuvant chemotherapy in cervical carcinoma with gemcitabine is helpful for achieving good response .As radiation sensitizer or radio-potentiator,gemcitabine can promote efficacy of neoadjuvant chemotherapy in cervical carcinoma.

关 键 词：吉西他滨 宫颈癌 新辅助化疗 

分 类 号：R737.33[医药卫生—肿瘤]